FR2906724B1 - Methode d'immunisation contre les 4 serotypes de la dengue. - Google Patents

Methode d'immunisation contre les 4 serotypes de la dengue.

Info

Publication number
FR2906724B1
FR2906724B1 FR0608660A FR0608660A FR2906724B1 FR 2906724 B1 FR2906724 B1 FR 2906724B1 FR 0608660 A FR0608660 A FR 0608660A FR 0608660 A FR0608660 A FR 0608660A FR 2906724 B1 FR2906724 B1 FR 2906724B1
Authority
FR
France
Prior art keywords
serotypes
dengue
immunization against
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0608660A
Other languages
English (en)
French (fr)
Other versions
FR2906724A1 (fr
Inventor
Bruno Guy
Remi Forrat
Jean Lang
Veronique Barban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Sanofi Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA filed Critical Sanofi Pasteur SA
Priority to FR0608660A priority Critical patent/FR2906724B1/fr
Priority to TW102119488A priority patent/TW201336508A/zh
Priority to TW096135167A priority patent/TWI406673B/zh
Priority to ARP070104316A priority patent/AR063057A1/es
Priority to KR1020097008657A priority patent/KR20090064593A/ko
Priority to PCT/FR2007/052054 priority patent/WO2008047023A2/fr
Priority to EP11192672A priority patent/EP2526965A1/fr
Priority to AU2007311792A priority patent/AU2007311792B2/en
Priority to EP11192665A priority patent/EP2526964A1/fr
Priority to EP07858487.7A priority patent/EP2077857B1/fr
Priority to CA002663885A priority patent/CA2663885A1/en
Priority to CN2007800444299A priority patent/CN101553251B/zh
Priority to CN201310128837XA priority patent/CN103285386A/zh
Priority to BRPI0719849-3A2A priority patent/BRPI0719849A2/pt
Priority to MX2009003417A priority patent/MX2009003417A/es
Priority to US11/866,382 priority patent/US7718358B2/en
Priority to JP2009530916A priority patent/JP5269796B2/ja
Priority to ZA200901816A priority patent/ZA200901816B/xx
Publication of FR2906724A1 publication Critical patent/FR2906724A1/fr
Application granted granted Critical
Publication of FR2906724B1 publication Critical patent/FR2906724B1/fr
Priority to IL197768A priority patent/IL197768A0/en
Priority to US12/718,308 priority patent/US20100270202A1/en
Priority to IL224572A priority patent/IL224572A/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0608660A 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue. Expired - Fee Related FR2906724B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
TW102119488A TW201336508A (zh) 2006-10-04 2007-09-20 對抗４種登革熱血清型之免疫方法
TW096135167A TWI406673B (zh) 2006-10-04 2007-09-20 對抗４種登革熱血清型之免疫方法
ARP070104316A AR063057A1 (es) 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue
US11/866,382 US7718358B2 (en) 2006-10-04 2007-10-02 Method of immunization against the 4 dengue serotypes
EP11192672A EP2526965A1 (fr) 2006-10-04 2007-10-02 Méthode d'immunisation contre les 4 sérotypes de la Dengue
AU2007311792A AU2007311792B2 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
EP11192665A EP2526964A1 (fr) 2006-10-04 2007-10-02 Méthode d'immunisation contre les 4 sérotypes de la Dengue
EP07858487.7A EP2077857B1 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue
CA002663885A CA2663885A1 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
KR1020097008657A KR20090064593A (ko) 2006-10-04 2007-10-02 4 가지 뎅기열 혈청형에 대한 면역화 방법
CN201310128837XA CN103285386A (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
BRPI0719849-3A2A BRPI0719849A2 (pt) 2006-10-04 2007-10-02 Método de imunização contra os quatro sorotipos da dengue
MX2009003417A MX2009003417A (es) 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue.
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue
JP2009530916A JP5269796B2 (ja) 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法
ZA200901816A ZA200901816B (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
CN2007800444299A CN101553251B (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
IL197768A IL197768A0 (en) 2006-10-04 2009-03-23 Immunisation method against the 4 dengue serotypes
US12/718,308 US20100270202A1 (en) 2006-10-04 2010-03-05 Method of Immunization Against the 4 Dengue Serotypes
IL224572A IL224572A (en) 2006-10-04 2013-02-04 A kit for neutralizing antibodies against the four types of dengue virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Publications (2)

Publication Number Publication Date
FR2906724A1 FR2906724A1 (fr) 2008-04-11
FR2906724B1 true FR2906724B1 (fr) 2009-03-20

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0608660A Expired - Fee Related FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Country Status (15)

Country Link
US (2) US7718358B2 (enExample)
EP (3) EP2526965A1 (enExample)
JP (1) JP5269796B2 (enExample)
KR (1) KR20090064593A (enExample)
CN (2) CN101553251B (enExample)
AR (1) AR063057A1 (enExample)
AU (1) AU2007311792B2 (enExample)
BR (1) BRPI0719849A2 (enExample)
CA (1) CA2663885A1 (enExample)
FR (1) FR2906724B1 (enExample)
IL (2) IL197768A0 (enExample)
MX (1) MX2009003417A (enExample)
TW (2) TWI406673B (enExample)
WO (1) WO2008047023A2 (enExample)
ZA (1) ZA200901816B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2010141386A1 (en) * 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
EP2473624B1 (en) 2009-08-31 2019-05-01 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10238734B2 (en) * 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
SG195115A1 (en) * 2011-06-29 2013-12-30 Immunotope Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
EP2858668A1 (en) * 2012-06-10 2015-04-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
JP2015524421A (ja) * 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CA2933472A1 (en) * 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
WO2014204892A1 (en) 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
MY192543A (en) 2014-12-22 2022-08-26 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
TWI736563B (zh) * 2015-11-27 2021-08-21 日商Ｋｍ生物醫藥股份有限公司 庫存之登革熱病毒減毒株的活病毒及以此等做為抗原之登革熱疫苗
US11690903B2 (en) 2017-10-05 2023-07-04 Sanofi Pasteur Compositions for booster vaccination against dengue
KR20210071979A (ko) 2018-09-05 2021-06-16 다케다 백신즈 인코포레이티드 뎅기열 백신 단위 용량 및 이의 투여
KR20220049023A (ko) 2019-08-16 2022-04-20 다케다 백신즈 인코포레이티드 뎅기열 및 a형 간염을 예방하기 위한 방법
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
DE69830579T2 (de) 1997-02-28 2006-05-04 Acambis, Inc., Cambridge Chimäre impfstoffe gegen flaviviren
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
CA2365728A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-1 virus vaccine
AU4040400A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
US6528065B1 (en) 1999-03-26 2003-03-04 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-3 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
ATE526411T1 (de) 2000-02-16 2011-10-15 Us Gov Health & Human Serv Avirulente, immunogene flavivirus-chimäre
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
ES2533085T3 (es) 2001-05-22 2015-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Desarrollo de mutaciones útiles para atenuar virus del dengue y virus del dengue quiméricos
JP2005518332A (ja) 2001-05-23 2005-06-23 デンドレオン コーポレイション 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
AU2002322026B2 (en) 2001-06-01 2008-03-13 Acambis Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
US7459160B2 (en) * 2002-01-15 2008-12-02 Acambis Inc. Chimeric flaviviruses
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
CN1791433B (zh) * 2003-03-24 2010-05-26 斯克里普斯研究学院 抗肿瘤生长的dna疫苗及其使用方法
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
US20100270202A1 (en) 2010-10-28
AU2007311792B2 (en) 2013-05-02
JP5269796B2 (ja) 2013-08-21
AU2007311792A1 (en) 2008-04-24
ZA200901816B (en) 2010-06-30
US7718358B2 (en) 2010-05-18
EP2526964A1 (fr) 2012-11-28
EP2077857B1 (fr) 2013-11-20
CN103285386A (zh) 2013-09-11
CA2663885A1 (en) 2008-04-24
WO2008047023A2 (fr) 2008-04-24
JP2010505801A (ja) 2010-02-25
US20080085288A1 (en) 2008-04-10
TW201336508A (zh) 2013-09-16
AR063057A1 (es) 2008-12-23
TWI406673B (zh) 2013-09-01
EP2077857A2 (fr) 2009-07-15
MX2009003417A (es) 2009-04-09
FR2906724A1 (fr) 2008-04-11
IL197768A0 (en) 2011-08-01
KR20090064593A (ko) 2009-06-19
WO2008047023A3 (fr) 2008-10-23
CN101553251A (zh) 2009-10-07
EP2526965A1 (fr) 2012-11-28
CN101553251B (zh) 2013-05-22
BRPI0719849A2 (pt) 2014-04-29
TW200826959A (en) 2008-07-01
IL224572A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
FR2906724B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
ZA200900155B (en) Method of immunisation against the four serotypes of dengue
PL1896065T3 (pl) Sposób wytwarzania szczepionek
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
DK2077287T3 (da) Fremgangsmåde til fremstilling af blødt polyurethanskum
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
PL2035398T3 (pl) Immobilizowany 1,2-benzoizotiazolin-3-on
NO346368B1 (no) En fremgangsmåte for konsentrasjon av alfa-mannosidase.
WO2006091722A3 (en) Alkyl-glycoside enhanced vaccination
BRPI0822079A2 (pt) Método, fluido de tratamento ácido, e, composição
CL2007002727A1 (es) Proceso de preparacion de anastrozol; y compuestos intermediarios.
FR2909743B1 (fr) Joint d'etancheite.
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
EP1904097A4 (en) MALARIA MSP-1 C-TERMINAL REINFORCED SUBUNIT VACCINE
BRPI0818783A2 (pt) Método de preparação de (6r)-3-hexil-4-hidróxi-6-undecil-5,6-diidropirano-2-ona, e intermediário empregado no método
ITMO20060388A1 (it) Metodo per la realizzazione di manufatti fotoluminescenti e manufatto fotoluminescente cosi' ottenibile.
ITMI20051910A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
ITMI20062515A1 (it) Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
ITMI20061212A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
TH0601005638A (th) องค์ประกอบที่ประกอบรวมด้วยริทูซิแมบสำหรับรักษาความเสียหายของข้อ
ITUD20060244A1 (it) Metodo per la realizzazione di una struttura sportiva multifunzionale, e struttura sportiva multifunzionale cosi' realizzata

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20170630